Page last updated: 2024-10-19
phenylacetic acid and Carbamoyl Phosphate Synthase (Ammonia) Deficiency Disease
phenylacetic acid has been researched along with Carbamoyl Phosphate Synthase (Ammonia) Deficiency Disease in 1 studies
phenylacetic acid : A monocarboxylic acid that is toluene in which one of the hydrogens of the methyl group has been replaced by a carboxy group.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|
| "We report the results of a 25-year, open-label, uncontrolled study of sodium phenylacetate and sodium benzoate therapy (Ammonul, Ucyclyd Pharma) in 299 patients with urea-cycle disorders in whom there were 1181 episodes of acute hyperammonemia." | 5.12 | Survival after treatment with phenylacetate and benzoate for urea-cycle disorders. ( Berry, GT; Berry, SA; Brusilow, SW; Enns, GM; Hamosh, A; Rhead, WJ, 2007) |
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|
| Enns, GM | 1 |
| Berry, SA | 1 |
| Berry, GT | 1 |
| Rhead, WJ | 1 |
| Brusilow, SW | 1 |
| Hamosh, A | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status |
|---|
| A Phase 2, Open-Label, Switch-Over, Dose-Escalation Study of the Safety and Tolerability of HPN-100 Compared to Buphenyl® (Sodium Phenylbutyrate) in Patients With Urea Cycle Disorders[NCT00551200] | Phase 2 | 14 participants (Actual) | Interventional | 2007-10-31 | Completed |
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Number of Subjects Experienced Adverse Events
(NCT00551200)
Timeframe: during the period on 100% Buphenyl (up to 4 weeks) or HPN-100 (up to 10 weeks)
| Intervention | participants (Number) |
|---|
| Buphenyl | 7 |
| HPN-100 | 5 |
Number of Subjects Experienced Serious Adverse Events
(NCT00551200)
Timeframe: during the period subjects on 100% Buphenyl (up to 4 weeks) or HPN-100 (up to 10 weeks)
| Intervention | participants (Number) |
|---|
| Buphenyl | 1 |
| HPN-100 | 0 |
Drug Preference for HPN-100 or Buphenyl® (as Assessed by Global Preference Question)
(NCT00551200)
Timeframe: End of Study
| Intervention | participants (Number) |
|---|
| prefer Buphenyl | prefer HPN-100 |
|---|
| Buphenyl to HPN-100 | 1 | 9 |
Pharmacokinetics (Plasma and Urine PK Parameters of Study Drugs and Their Metabolites)
measured AUC0-24 (Area under the curve from time 0 (pre-dose) to 24 hours) for each metabolite in plasma. Data were collected at 30 minutes and 1, 2, 4, 5, 6, 8, 10, 12, and 24 hours post-first dose. (NCT00551200)
Timeframe: At steady state (1 week) on each medication (Buphenyl® alone, HPN-100 alone)
| Intervention | μg*h/mL (Mean) |
|---|
| AUC0-24 PBA (phenylbutyrate) in plasma | AUC0-24 PAA (phenylacetate) in plasma | AUC0-24 PAGN (phenylacetylglutamine) in plasma |
|---|
| HPN-100 Steady State | 540 | 575 | 1098 |
,| NaPBA Steady State | 740 | 596 | 1133 |
Venous Ammonia Levels at the Peak and Mean TNUAC Time-normalized Area Under the Curve)
Data were collected at pre-first dose and at 30 minutes and 1, 2, 4, 5, 6, 8, 10, 12, and 24 hours post first dose. (NCT00551200)
Timeframe: At steady state (1 week) on each medication (Buphenyl® alone, HPN-100 alone), and at steady state (1 week) after each dose escalation
| Intervention | μmol/L (Mean) |
|---|
| in peak | in TNAUC (time-normalized area under the curve) |
|---|
| HPN-100 Steady State | 56.3 | 26.5 |
,| NaPBA Steady State | 79.1 | 38.4 |
Trials
1 trial available for phenylacetic acid and Carbamoyl Phosphate Synthase (Ammonia) Deficiency Disease